Global Hepatitis Partnering 2010 to 2016
[Lowest Price Guaranteed: $1,495]
Published by Current Partnering: 01 Nov 2016 | 20379 | In Stock
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world’s leading healthcare companies.
• Trends in partnering deals
• Top deals by value
• Deals listed by company A-Z, industry sector, stage of development, technology type
The report provides understanding and access to the partnering deals and agreements entered into by the world’s leading healthcare companies.
The report provides an analysis of partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
This data driven report contains multiple links to online copies of actual deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of partnering trends.
Chapter 1 provides an overview of the trends in partnering since 2010, including a summary of deals by industry sector, stage of development, deal type, and technology type.
Chapter 2 provides a review of the top 10 most active companies in the therapy area, including a comprehensive listing of the deals announced by each company.
Chapter 3 provides a comprehensive directory of partnering deals signed and announced since 2010. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.
Chapter 4 provides a listing of partnering deals where a contract document is available alongside the deal record.
Chapters 5 and 6 provide a summary of M&A deals since 2010 where the acquired company is active in the therapy area of interest.
Chapters 7 and 8 provide a summary of financings since 2010 where the financed company is active in the therapy area of interest.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of technologies and products in the therapy area.
Table of Contents
for Global Hepatitis Partnering 2010 to 2016
Chapter 1 - Therapypartnering trends in numbers
Partnering in numbers – by year
Partnering in numbers – most active
Partnering in numbers – by industry sector
Partnering in numbers – by deal type
Partnering in numbers – by technology type
Partnering in numbers – by stage of development
Chapter 2 - Most active dealmakers
Chapter 3 - Partnering deals directory
Partnering deals directory – by company A-Z
Partnering deals directory – by deal value
Partnering deals directory – by industry sector
Partnering deals directory – by deal type
Partnering deals directory – by stage of development
Partnering deals directory – by technology area
Chapter 4 - Partnering deals with a contract document
Chapter 5 - M&A in numbers
M&A in numbers – by year
Chapter 6 - M&A deals directory
M&A deals directory – by company A-Z
M&A deals directory – by deal value
Chapter 7 - Financing in numbers
Financing in numbers – by year
Financing in numbers – by financing type
Chapter 8 - Financing deals directory
Financing deals directory – by company A-Z
Financing deals directory – by deal value
Financing deals directory – by financing type
About Wildwood Ventures
Recent titles from CurrentPartnering
TABLE OF FIGURES
Figure 1: Partnering frequency by year
Figure 2: Partnering most active
Figure 3: Partnering by industry sector
Figure 4: Partnering by deal type
Figure 5: Partnering by technology area
Figure 6: Partnering by stage of development
Figure 7: M&A frequency by year
Figure 8: Financing frequency by year
Figure 9: Financing by type
20379 | CP2206hep
Number of Pages
|Title||Date Published||Price from||More Details|
|Global Hepatitis Partnering 2010 to 2016|
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
|01 Oct 2016 by Current Partnering||USD $1,495||More Info|
|Hepatitis C: Update Bulletin [February 2016]|
IntroductionGain new KOL insights on the latest events that have the potential to shape the hepatiti...
|01 Feb 2016 by FirstWord Pharma||USD $995||More Info|
|Hepatitis C: KOL Insight|
IntroductionThe Hepatitis C (HCV) market will be driven by meeting the needs of under-served patient...
|01 Sep 2015 by FirstWord Pharma||USD $7,900||More Info|
|Physician Views: The hepatitis C pricing war - what impact on prescribers?|
Scope In a surprise move, AbbVie agreed last month to provide its newly approved hepatitis C drug Vi...
|29 Jan 2015 by FirstWord Pharma||USD $695||More Info|
|Payer Insights: Hepatitis C|
IntroductionThe race is on for the company that can competitively price treatment regimens, share da...
|26 Sep 2014 by FirstWord Pharma||USD $7,900||More Info|
|Physician Views: Sovaldi revolutionises hepatitis C in the US, but what about uptake in the EU5?|
Scope Uptake and usage of Gilead Sciences' Sovaldi (sofosbuvir) in the US market has been closely tr...
|08 Jul 2014 by FirstWord Pharma||USD $695||More Info|
|Physician Views – As hepatitis revolution gains pace, what are physician expectations for EASL 2014?|
Scope With this year's meeting of the International Liver Congress (EASL) just over a week away (Apr...
|01 Apr 2014 by FirstWord Pharma||USD $695||More Info|
|Hepatitis C: Game changing regimens to revolutionise treatment landscape - Consensus Outlook|
IntroductionThe worldwide hepatitis C (HCV) market is forecast to grow from .7 billion in 2012 to ...
|01 Dec 2013 by FirstWord Pharma||USD $4,995||More Info|
|Physician Views: Entering the post-interferon era – will Gilead Sciences dominate hepatitis C?|
Scope Consensus forecasts indicate that Gilead Sciences will dominate the market for all oral, inter...
|01 Nov 2013 by FirstWord Pharma||USD $695||More Info|
|Physician Views: What opportunity for Gilead Sciences' hepatitis C therapy sofosbuvir before interferon-sparing regiments reach the market?|
ScopeOne of the key features of the hepatitis C treatment landscape over the past year to 18 months ...
|01 Oct 2013 by FirstWord Pharma||USD $695||More Info|
This report is published by Current Partnering
Download Free Report Summary PDF
Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.
Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.
Accepted Card Types
Buy now using our secure payment system.